U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06835296) titled 'A Study of Oral YUQ-A1007 in Healthy Volunteers' on Dec. 23, 2024.
Brief Summary: YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD.
YUQ-A1007 has not been evaluated in human clinical studies. This study is first-in-human (FIH) study of YUQ-A1007. The goal of this trial is to evaluate the safety, tolerability, and pharmacokinetics of oral YUQ-A1007.
Study Start Date: Feb. 22
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, a...